Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem

Keyphrases

• Vancomycin 100%
• Critically Ill Patients 100%
• Acute Kidney Injury 100%
• Piperacillin-tazobactam 100%
• Meropenem 100%
• Cefepime 100%
• Confidence Interval 10%
• Retrospective Cohort Study 10%
• Odds Ratio 10%
• Multivariate Analysis 10%
• High Incidence 10%
• Empiric Antibiotics 10%
• Intensive Care Unit 10%
• University Hospital 10%
• Lactams 10%
• Non-critically Ill 10%
• Kidney Disease Improving Global Outcomes 10%

Nursing and Health Professions

• Vancomycin 100%
• Cefepime 100%
• Acute Kidney Failure 100%
• Piperacillin Plus Tazobactam 100%
• Meropenem 100%
• Odds Ratio 10%
• Confidence Interval 10%
• Cohort Analysis 10%
• Multivariate Analysis 10%
• Practice Guideline 10%
• Intensive Care Unit 10%
• University Hospital 10%
• Antibiotic Therapy 10%
• Kidney Disease 10%
• Lactam 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Kidney Failure 100%
• Vancomycin 100%
• Piperacillin Plus Tazobactam 100%
• Cefepime 100%
• Meropenem 100%
• Cohort Study 10%
• Antibiotic Therapy 10%
• Kidney Disease 10%
• Lactam 10%